NCT02933502View on ClinicalTrials.gov

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

September 20, 2017

Study Completion Date

January 2, 2018

Conditions
Scalp Psoriasis
Interventions
DRUG

DSXS topical product

treatment daily for 28 days

Trial Locations (1)

10532

Taro Pharmaceuticals USA Inc., Hawthorne

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02933502 - Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product | Biotech Hunter | Biotech Hunter